UCB to Implement Corporate-Wide Biologics Registration System Based on Genedata Biologics
Industry adoption continues to advance for first-in-class data analysis and management platform for biologics R&D activities
March 22, 2011
Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced a major research informatics collaboration with UCB, the global biopharmaceutical company. Based on the Genedata BiologicsTM software solution, the first-in-class biologics data analysis and management platform, the collaboration aims to implement a corporate-wide biological registration system for UCB’s protein-based lead candidates. Genedata Biologics will support UCB’s discovery operations in lead-finding activities in the fields of central nervous system disorders and autoimmune and inflammatory disorders research conducted in the UK and Belgium.
“Central and consistent registration of all our biologics lead candidates is key to UCB’s R&D operations,” explained Hector Sanchez, senior director of R&D Informatics at UCB. “Our BioQuest system, based on Genedata Biologics, tracks all biologics molecules from early discovery to development, and gives the UCB R&D organization central access to all relevant information on these molecules. Genedata Biologics provides a modular and scalable platform supporting complex R&D workflows in a division-of-labor environment. It seamlessly integrates into an existing research informatics environment and supports the full process through automation, standardization, and integration.”
Genedata Biologics is a comprehensive biologics registration system. As an integrated data management platform, it enables consistent storage and referencing of all relevant biomaterials including antibodies and recombinant proteins, clones, vectors, plasmids, expression constructs, cell lines, and expression and purification batches. With tools to facilitate laboratory workflows, Genedata Biologics supports biologics material and data handovers among different laboratories, departments, sites, and external contract research organizations. It comes with a built-in registration engine for biologics molecules ensuring uniqueness of the respective molecules—for both classical Immunoglobulin G as well as next-generation format antibodies. The system’s built-in business logic enables seamless biologics registration, naming, association, searching, retrieving, analyzing, and reporting.
“We are very pleased that UCB has selected Genedata as a strategic partner to implement their central biologics registration platform, which supports their global biopharmaceutical R&D operations,” said Dr. Othmar Pfannes, CEO of Genedata. “This collaboration is another major milestone in Genedata’s continuing expansion into biologics R&D informatics. We will continue to invest significant resources to develop integrated data management and analysis solutions that increase the efficiency of a highly complex biologics R&D process.”
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8,000 people in about 40 countries, the company generated revenue of EUR 3.1 billion in 2009. UCB is listed on Euronext Brussels (symbol: UCB).
Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI in their R&D, spanning early discovery all the way to the clinic. Founded in 1997, Genedata is headquartered in Switzerland with additional offices in Germany, Japan, Singapore, the UK, and the US.
LinkedIn | Twitter | YouTube
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.